siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model

Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe...

Full description

Bibliographic Details
Main Authors: Jae Yun Jung, Hyun Jin Ryu, Seung-Hwan Lee, Dong-Young Kim, Myung Ji Kim, Eun Ji Lee, Yeon-Mi Ryu, Sang-Yeob Kim, Kyu-Pyo Kim, Eun Young Choi, Hyung Jun Ahn, Suhwan Chang
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cells
Subjects:
siRNA
nanoparticle
pancreatic cancer
PD-L1
immunotherapy
humanized NSG
Online Access:https://www.mdpi.com/2073-4409/10/10/2734

Internet

https://www.mdpi.com/2073-4409/10/10/2734

Similar Items